

PancreasFest 2024



INVITATION TO SUPPORT

July 25-26, 2024
The Westin
Cincinnati, Ohio



Collaborative Alliance
for Pancreatic Education
and Research



PancreasFest 2024

July 25-26, 2024
The Westin Cincinnati, Ohio



Special Update! *We're taking tradition to new heights as PancreasFest 2024 moves to Cincinnati, OH!*

The excitement continues as the Pancreas Club 2024 Annual Meeting immediately follows the PancreasFest 2024 both at the Westin Cincinnati.

Industry professionals can connect with a wider audience, immersed in pancreas-related fields, in one trip!

This seamless back-to-back arrangement means easier access for our valued industry partners.

Participate in PancreasFest, Pancreas Club or both!

ABOUT PANCREASFEST

WHY EXHIBIT AT PANCREASFEST?

The benefits to be gained from aligning your company with our high-profile pancreas event are substantial.

As a PancreasFest Exhibitor, you will have the opportunity to:

- Connect with the foremost experts in pancreas disease
- Leverage the back-to-back meetings for an expanded reach to a wider audience
- Enhance your company's presence and recognition
- Demonstrate thought leadership
- Expand your prospect base with low cost and effective reach
- Strengthen existing relationships
- Access scientific sessions with a meeting pass

EXHIBIT FEE

\$5,000 includes a 6' tabletop display, 2 exhibitor badges and recognition in the final program, meeting app, signage and session slides. Exhibitors will also receive a complimentary Meeting App Listing to maximize exposure!

[For more information, please visit our website.](#)



EDUCATIONAL GRANT

PancreasFest has a long history of quality academic research and welcomes educational grants and meeting support. If after reading the program you believe your company's current mission aligns with our program, please contact us at CAPER@lp-etc.com. Grants must comply with ACCME guidelines. Together with industry, CAPER continues to invest in advances in patient care.

PANCREASFEST TRAVEL SCHOLARSHIPS

Travel Scholarships will continue to be offered by CAPER, and are an integral component of CAPER's commitment to providing educational opportunities for young investigators, junior faculty, and trainees to pursue further educational development at the PancreasFest Annual Meeting.

Successful awardees will be invited to present their research at PancreasFest. Select industry partners will be recognized as a supporter of these scholarships at the live educational activity. See the sponsorship section for more information.



PancreasFest 2024

July 25-26, 2024
The Westin Cincinnati, Ohio



ABOUT CAPER



The Collaborative Alliance for Pancreatic Education and Research’s (CAPER) mission is to facilitate the collaboration of researchers of pancreatic diseases and to support scientifically rigorous multi-center studies in pancreatic diseases; to educate and train healthcare providers in pancreatic diseases; and to increase public health awareness regarding pancreatic diseases.

CAPER is devoted to the pursuit of clinical excellence in Gastroenterology and Hepatology, primarily through continuing medical education and mentorship. By providing a professional forum for pancreatologist experts and trainees to gather, CAPER aims to stimulate intellectual curiosity to improve outcomes for patients afflicted with pancreatic diseases.



CONTACT

Collaborative Alliance for Pancreatic Education and Research
913.402.7102 | CAPER@lp-etc.com | www.caperpancreas.org

EXECUTIVE COMMITTEE

PRESIDENT

Maisam Abu-El-Haija MD, MS
Cincinnati Children’s Hospital,
Cincinnati, OH

PRESIDENT-ELECT

Melena Bellin MD
University of Minnesota, Minneapolis, MN

IMMEDIATE PAST PRESIDENT

Gregory Cote MD
Oregon Health & Science University,
Portland, OR

CHAIR

Eric Golden
Fluent Partners, LLC, Los Angeles, CA

YOUNG INVESTIGATOR DIRECTOR

Mitchell Ramsey MD
The Ohio State University Wexner
Medical Center, Columbus, OH

BOARD OF DIRECTORS

- Maisam Abu-El-Haija MD, MS**
- Venkata Akshintala MD**
- Melena Bellin MD**
- Christine Cataldo**
- Gregory Cote MD**
- Jay Freeman MD**
- Eric Golden**
- Samuel Han MD, MS**
- Steven Hughes MD**
- Meaghan Petersak-Cannon**
- Elham Affghani MD**
- Christyn Taylor**
- Georgios Papachristou MD, PhD**
- Walter Park MD**
- Anna Evans Phillips MD**
- Skip Purich MD**
- Mitchell Ramsey MD**
- David Troendle MD**
- Dhiraj Yadav MD**
- Nicholas Zyromski MD**

EMERITUS MEMBERS

- Ms. Patter Birsic**
- Randall E. Brand, MD**
- David Whitcomb, MD, PhD**

Investing in the Future of Pancreatology

CAPER is pleased to offer the following opportunities, outside of the PancreasFest Annual Meeting, for industry to partner and collaborate on pancreatic research.

CAPER/NPF VISITING FELLOWS PROGRAM


The Collaborative Alliance for Pancreatic Education and Research (CAPER) and The National Pancreas Foundation (NPF) are pleased to offer the CAPER/NPF Visiting Fellows Program. This opportunity features a one-month immersive experience for select trainees to be exposed to a comprehensive and multidisciplinary approach to the management of benign and malignant pancreatic diseases. Two Visiting Fellowships will be awarded. One Visiting Fellow will be hosted at the University of Pittsburgh Medical Center for an adult pancreatology experience and one visiting fellow will be hosted at Cincinnati Children's Hospital Medical Center for a pediatric pancreatology experience. By electing to support this program, your company will receive recognition on promotions distributed through CAPER and NPF marketing channels. For more information on this program, please [click here](#).

PANCREAS ACADEMY


The CAPER Pancreas Academy seeks to deliver a comprehensive educational update by thought leaders in the field of pancreatology through a virtual webinar series. The target audience for this educational initiative is gastroenterologists, internal medicine, general and family practitioners, physician assistants, nurse practitioners, and any other person who seeks to improve their clinical knowledge of both benign and malignant pancreatic diseases. The educational content is developed by nationally renowned clinicians who will serve as faculty. By electing to support this program, your company will receive recognition on promotions, webinars and on-demand recordings. For more information on this program, please [click here](#).

CAPER SCHOLARS - MEET THE MENTORS

	Maisam Abu-El-Hajja MD, MS Cincinnati Children's Hospital Medical Center		Melena Bellin MD University of Minnesota		Steven Hughes MD University of Florida
	David Troendle MD UT Southwestern		Georgios Papachristou MD The Ohio State University		Walter Park MD Stanford University
			Dhiraj Yadav MD, MPH University of Pittsburgh		




Webinar Title: INSPIRE International Study Group of Pancreatic Pancreatitis: In Search of a Cure!
Presenter: Dr. Ajay Sah, Sted Family Department of Pediatrics, Iowa City, Iowa




Webinar Title: Bridging the Gap Between Pediatric and Adult Pancreatology
Presenter: Dr. Sohail Husain, Stanford Children's Hospital

Your Branding Could Be Here



Webinar Title: Grant Preparation and Writing
Presenter: Dr. Walter Park, Stanford Health Care



Webinar Title: Lessons Learned
Presenter: Dr. Peter Banks, Brigham and Women's Hospital, Harvard Medical School

CAPER PANCREAS SCHOLARS

The CAPER Pancreas Scholars Program is a two-year, educational mentorship program, consisting of a live mentorship workshop, quarterly webinars, and monthly mentorship teleconferences. Each scholar, with oversight by the faculty mentors, will work on a cumulative research project. By electing to support this program, your company will receive recognition on promotions and workshop materials. For more information on this program, please [click here](#).

YOUNG INVESTIGATOR WEBINAR SERIES

These highly anticipated CAPER webinars feature renowned experts discussing sought after information with trainees and young investigators. The goal of this webinar series is to promote and conduct inter-institutional, multidisciplinary, and collaborative pancreatic research projects through networking. By electing to support this program, your company will receive recognition on promotions, webinars and on-demand recordings. For more information on this program, please [click here](#).

Visceral artery pseudoaneurysms in resecting pancreatitis

Baseline characteristics	N (%)
Most common arteries involved by PSA	
Splenic	19 (88.7%)
Gastroduodenal	11 (52.7%)
Pancreaticoduodenal	5 (23.8%)
Median size of PSA (in mm)	14.8 (8.2-25.9)

Clinical presentation	N (%)
Asymptomatic	28 (77%)
Abdominal pain	18 (82.7%)
Abdominal pain	17 (81.4%)

Median time of development of PSA from WP diagnosis after LAMS vs. non-LAMS resection in days
44 (20) (13.3-86 vs. 83 (27) (6-138))

Choice of transarterial stents did not determine the incidence of PSA
An earlier incidence of PSA was identified in patients with LAMS (44 days vs. 85 days, P=0.009)
Abdolkhan M., Yikrazhanelian C, GE 2020

Pancreatogenic diabetes, also known as type 3c diabetes

Table 3 - Etiologic classification of diabetes mellitus

1. Type 1 diabetes (T1D) autoimmune, usually leading to absolute insulin deficiency
 - A. Immune mediated
 - A. Idiopathic
2. Type 2 diabetes (T2D) ranges from predominantly insulin resistance with relative insulin deficiency to a predominantly secretory defect with insulin resistance
 - A. Other specific types
 1. Genetic defects of beta cell function
 2. MODY 1 (Chromosomes 2q, 9q, 12q)
 3. MODY 2 (Chromosomes 2q, 9q, 12q)
 4. MODY 3 (Chromosomes 2q, 9q, 12q)
 5. Other very rare forms of MODY (e.g., MODY 4 (Chromosomes 11, 12q), MODY 5 (Chromosomes 1, 9q, 12q), MODY 6 (Chromosomes 1, 9q, 12q), MODY 7 (Chromosomes 1, 9q, 12q), MODY 8 (Chromosomes 1, 9q, 12q), MODY 9 (Chromosomes 1, 9q, 12q), MODY 10 (Chromosomes 1, 9q, 12q), MODY 11 (Chromosomes 1, 9q, 12q), MODY 12 (Chromosomes 1, 9q, 12q), MODY 13 (Chromosomes 1, 9q, 12q), MODY 14 (Chromosomes 1, 9q, 12q), MODY 15 (Chromosomes 1, 9q, 12q), MODY 16 (Chromosomes 1, 9q, 12q), MODY 17 (Chromosomes 1, 9q, 12q), MODY 18 (Chromosomes 1, 9q, 12q), MODY 19 (Chromosomes 1, 9q, 12q), MODY 20 (Chromosomes 1, 9q, 12q), MODY 21 (Chromosomes 1, 9q, 12q), MODY 22 (Chromosomes 1, 9q, 12q), MODY 23 (Chromosomes 1, 9q, 12q), MODY 24 (Chromosomes 1, 9q, 12q), MODY 25 (Chromosomes 1, 9q, 12q), MODY 26 (Chromosomes 1, 9q, 12q), MODY 27 (Chromosomes 1, 9q, 12q), MODY 28 (Chromosomes 1, 9q, 12q), MODY 29 (Chromosomes 1, 9q, 12q), MODY 30 (Chromosomes 1, 9q, 12q), MODY 31 (Chromosomes 1, 9q, 12q), MODY 32 (Chromosomes 1, 9q, 12q), MODY 33 (Chromosomes 1, 9q, 12q), MODY 34 (Chromosomes 1, 9q, 12q), MODY 35 (Chromosomes 1, 9q, 12q), MODY 36 (Chromosomes 1, 9q, 12q), MODY 37 (Chromosomes 1, 9q, 12q), MODY 38 (Chromosomes 1, 9q, 12q), MODY 39 (Chromosomes 1, 9q, 12q), MODY 40 (Chromosomes 1, 9q, 12q), MODY 41 (Chromosomes 1, 9q, 12q), MODY 42 (Chromosomes 1, 9q, 12q), MODY 43 (Chromosomes 1, 9q, 12q), MODY 44 (Chromosomes 1, 9q, 12q), MODY 45 (Chromosomes 1, 9q, 12q), MODY 46 (Chromosomes 1, 9q, 12q), MODY 47 (Chromosomes 1, 9q, 12q), MODY 48 (Chromosomes 1, 9q, 12q), MODY 49 (Chromosomes 1, 9q, 12q), MODY 50 (Chromosomes 1, 9q, 12q), MODY 51 (Chromosomes 1, 9q, 12q), MODY 52 (Chromosomes 1, 9q, 12q), MODY 53 (Chromosomes 1, 9q, 12q), MODY 54 (Chromosomes 1, 9q, 12q), MODY 55 (Chromosomes 1, 9q, 12q), MODY 56 (Chromosomes 1, 9q, 12q), MODY 57 (Chromosomes 1, 9q, 12q), MODY 58 (Chromosomes 1, 9q, 12q), MODY 59 (Chromosomes 1, 9q, 12q), MODY 60 (Chromosomes 1, 9q, 12q), MODY 61 (Chromosomes 1, 9q, 12q), MODY 62 (Chromosomes 1, 9q, 12q), MODY 63 (Chromosomes 1, 9q, 12q), MODY 64 (Chromosomes 1, 9q, 12q), MODY 65 (Chromosomes 1, 9q, 12q), MODY 66 (Chromosomes 1, 9q, 12q), MODY 67 (Chromosomes 1, 9q, 12q), MODY 68 (Chromosomes 1, 9q, 12q), MODY 69 (Chromosomes 1, 9q, 12q), MODY 70 (Chromosomes 1, 9q, 12q), MODY 71 (Chromosomes 1, 9q, 12q), MODY 72 (Chromosomes 1, 9q, 12q), MODY 73 (Chromosomes 1, 9q, 12q), MODY 74 (Chromosomes 1, 9q, 12q), MODY 75 (Chromosomes 1, 9q, 12q), MODY 76 (Chromosomes 1, 9q, 12q), MODY 77 (Chromosomes 1, 9q, 12q), MODY 78 (Chromosomes 1, 9q, 12q), MODY 79 (Chromosomes 1, 9q, 12q), MODY 80 (Chromosomes 1, 9q, 12q), MODY 81 (Chromosomes 1, 9q, 12q), MODY 82 (Chromosomes 1, 9q, 12q), MODY 83 (Chromosomes 1, 9q, 12q), MODY 84 (Chromosomes 1, 9q, 12q), MODY 85 (Chromosomes 1, 9q, 12q), MODY 86 (Chromosomes 1, 9q, 12q), MODY 87 (Chromosomes 1, 9q, 12q), MODY 88 (Chromosomes 1, 9q, 12q), MODY 89 (Chromosomes 1, 9q, 12q), MODY 90 (Chromosomes 1, 9q, 12q), MODY 91 (Chromosomes 1, 9q, 12q), MODY 92 (Chromosomes 1, 9q, 12q), MODY 93 (Chromosomes 1, 9q, 12q), MODY 94 (Chromosomes 1, 9q, 12q), MODY 95 (Chromosomes 1, 9q, 12q), MODY 96 (Chromosomes 1, 9q, 12q), MODY 97 (Chromosomes 1, 9q, 12q), MODY 98 (Chromosomes 1, 9q, 12q), MODY 99 (Chromosomes 1, 9q, 12q), MODY 100 (Chromosomes 1, 9q, 12q)
 2. Genetic defects in insulin action
 3. Type 2 diabetes resistance
 4. Lipid abnormalities
 5. Adipose tissue dysfunction
 6. Lipid abnormalities
 7. Lipid abnormalities
 8. Lipid abnormalities
 9. Lipid abnormalities
 10. Lipid abnormalities
 11. Lipid abnormalities
 12. Lipid abnormalities
 13. Lipid abnormalities
 14. Lipid abnormalities
 15. Lipid abnormalities
 16. Lipid abnormalities
 17. Lipid abnormalities
 18. Lipid abnormalities
 19. Lipid abnormalities
 20. Lipid abnormalities
 21. Lipid abnormalities
 22. Lipid abnormalities
 23. Lipid abnormalities
 24. Lipid abnormalities
 25. Lipid abnormalities
 26. Lipid abnormalities
 27. Lipid abnormalities
 28. Lipid abnormalities
 29. Lipid abnormalities
 30. Lipid abnormalities
 31. Lipid abnormalities
 32. Lipid abnormalities
 33. Lipid abnormalities
 34. Lipid abnormalities
 35. Lipid abnormalities
 36. Lipid abnormalities
 37. Lipid abnormalities
 38. Lipid abnormalities
 39. Lipid abnormalities
 40. Lipid abnormalities
 41. Lipid abnormalities
 42. Lipid abnormalities
 43. Lipid abnormalities
 44. Lipid abnormalities
 45. Lipid abnormalities
 46. Lipid abnormalities
 47. Lipid abnormalities
 48. Lipid abnormalities
 49. Lipid abnormalities
 50. Lipid abnormalities
 51. Lipid abnormalities
 52. Lipid abnormalities
 53. Lipid abnormalities
 54. Lipid abnormalities
 55. Lipid abnormalities
 56. Lipid abnormalities
 57. Lipid abnormalities
 58. Lipid abnormalities
 59. Lipid abnormalities
 60. Lipid abnormalities
 61. Lipid abnormalities
 62. Lipid abnormalities
 63. Lipid abnormalities
 64. Lipid abnormalities
 65. Lipid abnormalities
 66. Lipid abnormalities
 67. Lipid abnormalities
 68. Lipid abnormalities
 69. Lipid abnormalities
 70. Lipid abnormalities
 71. Lipid abnormalities
 72. Lipid abnormalities
 73. Lipid abnormalities
 74. Lipid abnormalities
 75. Lipid abnormalities
 76. Lipid abnormalities
 77. Lipid abnormalities
 78. Lipid abnormalities
 79. Lipid abnormalities
 80. Lipid abnormalities
 81. Lipid abnormalities
 82. Lipid abnormalities
 83. Lipid abnormalities
 84. Lipid abnormalities
 85. Lipid abnormalities
 86. Lipid abnormalities
 87. Lipid abnormalities
 88. Lipid abnormalities
 89. Lipid abnormalities
 90. Lipid abnormalities
 91. Lipid abnormalities
 92. Lipid abnormalities
 93. Lipid abnormalities
 94. Lipid abnormalities
 95. Lipid abnormalities
 96. Lipid abnormalities
 97. Lipid abnormalities
 98. Lipid abnormalities
 99. Lipid abnormalities
 100. Lipid abnormalities

American Diabetes Association. Diagnosis and Classification of Diabetes. Diabetes Care 2014; Jan; 37(Supplement 1): S81-S90.

Frequent opioid use in children with ARP/CP

- Of 427 children/adolescents with ARP or CP, 17% reported daily or weekly opioid use.
- Concurrent physician surveys on those with frequent opioid use reported opioid use less than weekly in 39% and were missing data on frequency in 18%.
- Children in the U.S. West and Midwest = 83% of children reporting frequent opioid use but only 14.5% of total cohort.

PancreasFest 2024

July 25-26, 2024
The Westin Cincinnati, Ohio



CAPER & PANCREASFEST OPPORTUNITIES

BENEFIT	DIAMOND	GOLD	SILVER	BRONZE	EXHIBIT ONLY
PancreasFest Recognition & Experiences	\$20,000	\$15,000	\$10,000	\$7,500	\$5,000
Industry Forum	45 mins.				
Email Blast to Meeting Attendees	Pre or Post (approved content)				
Choice Booth Location	✓				
PancreasFest Travel Scholarships Sponsor	✓	✓			
Registration Desk Sponsor	✓	✓			
PancreasFest Meeting App Push Notification	✓	✓			
Welcome Reception Promotion	✓	✓	✓		
Sponsored Session Choice	✓	✓	✓		
Logo on Daily Newsletter	✓	✓	✓		
Sponsorship Signage	✓	✓	✓	✓	
Walk-in Slide Recognition	✓	✓	✓	✓	
Podium Announcement	✓	✓	✓	✓	
Premium Exhibit Space	✓	✓	✓	✓	
Additional Booth Passes	4	3	2	1	
Recognition on Know Before you Go Email Blast	✓	✓	✓	✓	
Final Program	Full Page	Half Page	Half Page	Quarter Page	Listing
PancreasFest Attendee List	✓	✓	✓	✓	✓
PancreasFest Meeting App Listing	✓	✓	✓	✓	✓
Exhibit Hall Signage	✓	✓	✓	✓	✓
CAPER Recognition & Experiences					
CAPER/NPF Visiting Fellows Sponsor	✓				
Pancreas Academy Sponsor	✓	✓			
CAPER Pancreas Scholars Sponsor	✓	✓	✓		
Young Investigator Webinar Series	✓	✓	✓	✓	
Social Media Recognition	✓	✓	✓	✓	



PancreasFest 2024

July 25-26, 2024
The Westin Cincinnati, Ohio



REGISTRATION

DETAILS & FEES

COMPANY NAME *(Please list exactly as you would like it to appear on the recognition signage and name badges)*

CONTACT NAME PHONE NUMBER E-MAIL

Educational Grant \$ _____

Marketing / Exhibit Support \$ _____

Diamond Level Sponsorship — \$20,000 \$ _____

Gold Level Sponsorship — \$15,000 \$ _____

Silver Level Sponsorship — \$10,000 \$ _____

Bronze Level Sponsorship — \$7,500 \$ _____

PancreasFest Exhibit Fee — \$5,000 \$ _____

TOTAL DUE \$ _____

**PLEASE COMPLETE ALL SECTIONS
AND RETURN VIA EMAIL OR MAIL TO:**

CAPER
PO Box 219191
Kansas City, MO 64121-9191
913.402.7103
www.caperpancreas.org | CAPER@lp-etc.com
CAPER Tax ID: 26-3056180

PAYMENT INFORMATION

Check — Payable to 'CAPER' and mail to the address listed above.

Credit Card — Indicate credit card to be charged and email to CAPER@lp-etc.com: AmEx MC VISA Discover

NAME AS IT APPEARS ON CARD CARD NUMBER

EXPIRATION DATE SIGNATURE

CREDIT CARD BILLING ADDRESS CITY / STATE / ZIP

PAYMENT AND REFUNDS

Payment in full is due at the time of application. Applications received without such payment will not be processed nor will space assignments be made. All payments are non-refundable. By submitting a completed application to CAPER, you confirm to have read and agree to the Terms and Conditions on the following page.



PancreasFest 2024

July 25-26, 2024
The Westin Cincinnati, Ohio



TERMS AND CONDITIONS

PancreasFest and its authorized representatives are hereinafter referred to as "Show Management."

PAYMENT AND REFUNDS

Payment in full is due at the time of application. Applications received without such payment will not be processed nor will space assignments be made. All payments are non-refundable.

SPACE ASSIGNMENT

Whenever possible, space assignments will be made by Show Management in keeping with the preferences as to location requested by the exhibitor. SHOW MANAGEMENT, HOWEVER, RESERVES THE RIGHT TO MAKE THE FINAL DETERMINATION OF ALL SPACE ASSIGNMENTS IN THE BEST INTERESTS OF THE EXPOSITION.

EXHIBITS

Show Management reserves the right to restrict the operation of, or evict completely, any exhibit which, in its sole opinion, detracts from the general character of the exposition as a whole. No retail sales are permitted within the exhibit area at any time. No volatile or flammable fluids, substances or materials of any nature prohibited by city, fire regulation or insurance carriers may be used in any booth; all construction in a booth shall be substantial and fixed in position for the duration of the show; all aisles and exits must be kept clear, clean and free from obstructions to comply with fire restrictions. Live animals are prohibited. Distribution of material is limited to the area within the exhibitors trade show booth. Exhibitors shall not interfere with others ability to conduct trade show activities.

SECURITY

Routine hotel security will be provided. PancreasFest will not take responsibility for any loss or damage to any exhibit.

CONTACT

Collaborative Alliance for Pancreatic Education and Research
913.402.7102 | CAPER@lp-etc.com | www.caperpancreas.org



LIABILITY

It is agreed that individual exhibitors will protect, save and keep PancreasFest and Hotel from any damage or charges imposed for violation of any law or ordinance whether occasioned by the negligence of the exhibitor or those holding under the exhibitor, as well as to strictly comply with the applicable terms regarding the exhibition premises; and further exhibitor shall at times protect, indemnify, save and keep harmless the above parties against and from any and all loss, cost, damage, liability or expense arising from or out of or by reason of any accident or other occurrence to anyone, including the exhibitor, its agents, employees and business invitees, which arise from or out of or by reason of said exhibitor's occupancy and use of the exhibition premises or a part thereof.

INSURANCE

It is recommended that exhibitors obtain adequate insurance coverage, at their own expense, for property loss or damage and liability for personal injury.

AMERICANS WITH DISABILITIES ACT

Exhibitors acknowledge their responsibilities under the Americans with Disabilities Act (hereinafter "Act") to make their booths accessible to handicapped persons. Exhibitor shall also indemnify and hold harmless Show Management, and facility against cost, expense, liability or damage which may be incident to, arise out of or be caused by Exhibitor's failure to comply with the Act.

SHOW MANAGEMENT SHALL HAVE FULL POWER TO INTERPRET, AMEND, AND ENFORCE THESE RULES AND REGULATION, PROVIDED EXHIBITORS RECEIVE NOTICE OF ANY AMENDMENTS WHEN MADE. EACH EXHIBITOR AND ITS EMPLOYEES AGREES TO ABIDE BY THE FOREGOING RULES AND REGULATIONS AND BY ANY AMENDMENTS OR ADDITIONS THERETO IN CONFORMANCE WITH THE PRECEDING SENTENCE. EXHIBITORS OR THEIR REPRESENTATIVES WHO FAIL TO OBSERVE THESE CONDITIONS OF CONTRACT OR WHO, IN THE OPINION OF SHOW MANAGEMENT, CONDUCT THEMSELVES UNETHICALLY MAY IMMEDIATELY BE DISMISSED FROM THE EXHIBIT AREA WITHOUT REFUND OR OTHER APPEAL.